BPC-157 TB-500 is a two-peptide research blend studied for tissue repair — laid out here cell by cell.

Two peptides, one repair rationale

BPC-157 TB-500 is a research-community name for a two-peptide tissue-repair blend that pairs BPC-157, a 15-amino-acid cytoprotective peptide, with TB-500, a short actin-binding fragment of the protein Thymosin Beta-4. It is not a single chemical entity. It has no single molecular weight, no CAS number, and no approved therapeutic indication anywhere. What the BPC-157 TB-500 pairing offers is two separately characterized mechanisms placed side by side: a local cytoprotective and pro-angiogenic signal from BPC-157, and an intracellular cell-migration signal from TB-500.

The two components occupy complementary nodes of a tissue-repair network in preclinical work. BPC-157 up-regulates VEGFR2 with downstream Akt-eNOS signaling and promotes tendon and fibroblast outgrowth ^[2]. TB-500's LKKTETQ motif binds monomeric G-actin one-to-one, regulating the cytoskeletal dynamics that drive cell migration ^[3]. They act through complementary but largely non-overlapping pathways — which is the basis of the 'synergy' claim, and also the reason that claim remains theoretical.

This page is the index to the rest. It covers what the BPC-157 TB-500 blend is studied for, BPC-157 and TB-500 mechanisms, and BPC-157 TB-500 dosage in animal studies. Every quantitative claim across the site is attributed to a study in the reference list.

What Is the Wolverine Peptide Blend?

The Wolverine peptide blend is the research-community label for a co-formulated BPC-157 and TB-500 pairing, marketed and discussed as a tissue-repair 'stack.' The name is branding, not chemistry: 'Wolverine' describes a two-vial or single-vial combination, not a defined molecule. There is no PubChem CID, CAS number, or UNII for the blend as an entity — identifiers exist only per constituent.

BPC-157 is the cytoprotective leg. TB-500 is the cell-migration leg. The blend's literature is therefore two literatures: one for each peptide, each predominantly preclinical, joined by a rationale rather than a trial.

The Wolverine Stack: BPC-157 and TB-500 Combined

The Wolverine stack combines BPC-157 and TB-500 in fixed per-vial masses — commercial research-product labeling commonly pairs them at roughly 10 mg plus 10 mg, or a 20 mg combined vial. No peer-reviewed combination dose-finding study supports that ratio, and no controlled study has tested the assembled stack for any outcome ^[11].

The rationale offered for stacking is mechanistic complementarity. BPC-157 supplies the angiogenic and cytoprotective signal; TB-500's parent protein, Thymosin Beta-4, supplies cell migration, anti-scarring, and angiogenic activity through a separate route ^[4]. Pairing two pro-repair signals that act on different targets is the stated logic. It is a reasonable hypothesis. It is not a demonstrated result — see BPC-157 and TB-500 mechanisms for why researchers pair the two, and where the evidence stops.

How the blend is framed across this site

Because the Wolverine blend has no validated profile of its own, every figure on this site is captioned at the level it was actually measured. A finding from BPC-157 is tagged to BPC-157; a finding from TB-500 or its parent protein is tagged to TB-500; the blend itself carries the honest gap. BPC-157 has three small human pilot studies; the TB-500 heptapeptide has zero completed controlled human trials, and what human data exist for 'TB-500' were generated with full-length Thymosin Beta-4, not the 7-mer ^[5].

The regulatory picture is equally specific. Both constituents are research chemicals, neither is an FDA-approved drug, and both currently sit in the FDA's 503A 'Category 2' for compounding. The Wolverine legal status and FDA 503A category page sets out that record from the FDA source. For the safety questions — including the side effects and the tumor-signal concern — start with the FAQ.